Live Market Updates
Latest Financial News
News Feed
1 articles
Personalized
Live Market Updates
Latest Financial News
positive
4 days agoMapLight Therapeutics Soars 23% in Nasdaq Debut After $259 Million IPO
Biotechnology firm MapLight Therapeutics surged 23% on its first trading day following a $258.9 million initial public offering on Nasdaq. The San Francisco-based company priced shares at $17, giving it a post-IPO valuation of approximately $787 million. The proceeds will fund clinical trials for its neurodegenerative drug pipeline. Analysts said MapLight’s strong debut marks renewed investor interest in biotech listings after a sluggish IPO environment earlier this year. The stock closed well above its offer price, outperforming broader healthcare benchmarks.
Explore:Mutual Fund Themes
positive
4 days agoMapLight Therapeutics Soars 23% in Nasdaq Debut After $259 Million IPO
Biotechnology firm MapLight Therapeutics surged 23% on its first trading day following a $258.9 million initial public offering on Nasdaq. The San Francisco-based company priced shares at $17, giving it a post-IPO valuation of approximately $787 million. The proceeds will fund clinical trials for its neurodegenerative drug pipeline. Analysts said MapLight’s strong debut marks renewed investor interest in biotech listings after a sluggish IPO environment earlier this year. The stock closed well above its offer price, outperforming broader healthcare benchmarks.
Explore:Mutual Fund Themes
positive
MapLight Therapeutics Soars 23% in Nasdaq Debut After $259 Million IPO
4 days ago
1 min read
80 words
MapLight Therapeutics debuted on Nasdaq with a 23% gain after a $259 million IPO, signaling revived appetite for biotech equity offerings.
Biotechnology firm MapLight Therapeutics surged 23% on its first trading day following a $258.9 million initial public offering on Nasdaq. The San Francisco-based company priced shares at $17, giving it a post-IPO valuation of approximately $787 million. The proceeds will fund clinical trials for its neurodegenerative drug pipeline. Analysts said MapLight’s strong debut marks renewed investor interest in biotech listings after a sluggish IPO environment earlier this year. The stock closed well above its offer price, outperforming broader healthcare benchmarks.
Biotechnology firm MapLight Therapeutics surged 23% on its first trading day following a $258.9 million initial public offering on Nasdaq. The San Francisco-based company priced shares at $17, giving it a post-IPO valuation of approximately $787 million. The proceeds will fund clinical trials for its neurodegenerative drug pipeline. Analysts said MapLight’s strong debut marks renewed investor interest in biotech listings after a sluggish IPO environment earlier this year. The stock closed well above its offer price, outperforming broader healthcare benchmarks.
Companies:
MapLight Therapeutics
Tags:
IPO
biotech
IPO
biotech
MapLight
healthcare
Nasdaq
Oct 27, 2025 • 17:50 IST